Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

BLAZE-1 phase 2 (monotherapy), 2020 NCT04427501

bamlanivimab monotherapy (n=101) vs. placebo (n=156)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Bamlanivimab (LY-CoV555) 700 mg

Control treatment

placebo

5 arms: placebo, bamlanivimab 700 mg, 2800 mg, and 7000 mg and 2800 mg of bamlanivimab and 2800 mg of etesevimab

Patients

COVID 19 outpatients

Method

double-blind

Phase 2: exploratory trial, originally designed as a safety and biomarker study. Inconclusive for the primary endpoint.

Remark

As of April 2021, regulatory authorities recommend that bamlanivumab no longer be used because of the potential risk of treatment failure due to the circulation of resistant variants of SARS-CoV-2.